Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NQO1 | P15559 | 2/20 | 0.33 |
| ▸ | POR | P16435 | 2/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | BID | P55957 | 3/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.31 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.31 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.31 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16414569 | 0.83 | CA12 (0.39) | POLBTDP1L3MBTL1SMN1; SMN2ALOX15 | |
| SCHEMBL16144903 | 0.82 | NQO1 (0.32) | POLBTDP1L3MBTL1SMN1; SMN2ALOX15 | |
| SCHEMBL19020043 | 0.79 | CYP1A2 (0.39) | POLBTDP1L3MBTL1PTPN1PTPN11 | |
| SCHEMBL8654071 | 0.76 | FOLH1 (0.41) | POLBL3MBTL1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL16433085 | 0.76 | PTPN1 (0.40) | PTPN1PTPN11MAPTMETAP2BID | |
| SCHEMBL9860433 | 0.75 | SMN1; SMN2 (0.32) | PTPN1PTPN11SMN1; SMN2ALOX15MAPT | |
| SCHEMBL17866890 | 0.73 | BID (0.38) | PTPN1PTPN11ALDH1A1METAP2BID | |
| SCHEMBL17867211 | 0.72 | KAT8 (0.43) | ALOX15MAPTBIDMCL1BCL2L1 | |
| SCHEMBL17867056 | 0.71 | MAPT (0.32) | MAPTALDH1A1 | |
| SCHEMBL20550358 | 0.71 | ALDH1A1 (0.41) | POLBSMN1; SMN2MAPTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104529827-B | Ingenol-3-acylate III and ingenol-3-carbamate | 利奥实验室有限公司 | 2016-08-24 | — | — | CN | disclosed |
| CN-103402977-B | Ingenol-3-acylate III and ingenol-3-carbamate | LEO PHARMA A/S (IE) | 2016-01-20 | — | — | CN | disclosed |
| CN-104529827-A | Ingenol-3-acylates III and ingenol-3-carbamates | LEO PHARMA AS | 2015-04-22 | — | — | CN | disclosed |
| US-20140303150-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2014-10-09 | — | — | US | disclosed |
| CN-103402977-A | Ingenol-3-acylate III and Ingenol-3-carbamate | LEO PHARMA AS | 2013-11-20 | — | — | CN | disclosed |
| EP-2655323-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012083953-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303150-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | RXRB, RXRA, RXRG | POLB 3773/4885TDP1 4714/4885L3MBTL1 3703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.